[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401451":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":60,"collaborators":18,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":18,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":44,"whyStopped":18,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Ente Ospedaliero Cantonale, Bellinzona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"arm A","EXPERIMENTAL","• 9 mg of i.v. dexamethasone",[13],"Drug: dexamethasone",{"label":15,"type":16,"description":17,"interventionNames":18},"arm B","NO_INTERVENTION","• no steroid supplementation",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","dexamethasone","perioperatively 9 mg i.v subministration",[9],[26],"Steroids",[28],{"name":29,"affiliation":30,"role":31},"Christian Candrian, Prof.Dr.med","EOC","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","+41 (0) 91 811 61 23","christian.candrian@eoc.ch",{"name":38,"role":34,"phone":39,"phoneExt":18,"email":40},"Gyözö Lehoczky, Dr.med","+41918116431","Gyoezoe.Lehoczky@eoc.ch",[42],{"facility":43,"status":44,"city":45,"state":18,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Christian Candrian","RECRUITING","Lugano","6900","Switzerland","CH",{"type":50,"coordinates":51},"Point",[52,53],8.96004,46.01008,{"lat":53,"lon":52},[56,57],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},{"name":58,"role":34,"phone":18,"phoneExt":18,"email":59},"Gianluigi Capone, Dr.","gianluigi.capone@eoc.ch",{"type":61,"investigatorFullName":43,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Principal Investigator","100401451","phase-4-intravenous-dexamethasone-administration-in-patients-undergoing-total-shoulder-arthroplasty-100401451",false,"NCT04507412","Intravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty","Effect of Perioperative Intravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty for Osteoarthritis, in Terms of Post-operative Pain, Function, Nausea, Hospitalization Length, and Risk of Complications","Inclusion Criteria:\n\n* Patients undergoing unilateral primary total anatomical or reverse shoulder arthroplasty (Total Shoulder Arthroplasty)\n* Patients with a BMI \\>18.5 and \\\u003C35\n* Patients able to provide informed consent and follow all the study procedures as indicated by the protocol\n* Informed Consent as documented by signature\n\nExclusion Criteria:\n\n* Contraindications to steroids\n* Revision and post-traumatic TSA\n* Active steroid or immunosuppressive therapy in the last 30 days before the operation\n* Pregnant or breast-feeding women\n* Presence of other clinically significant concomitant disease states (ASA IV)\n* Uncontrolled diabetes mellitus\n* Contraindications to Non-steroidal anti-inflammatory drugs\n* Chronic systemic diseases as immunodeficiency, autoimmune disease (Systemic Lupus Erythematosus), gout, rheumatic arthritis\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons","ALL","58 Years","85 Years",{"count":74,"type":75},74,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The aim of the study is to evaluate if intravenous steroid supplementation can provide advantages over routine analgesia protocols in terms of post-operative symptoms (pain and nausea), length of hospital stay, shoulder range of motion, function and patient satisfaction",[81],"Arthroplasty, Replacement, Shoulder",[83,84],"Total Shoulder Arthroplasty","steroid","2026-03-03",{"date":87,"type":88},"2026-03-05","ACTUAL",{"date":90,"type":88},"2020-09-09",{"date":92,"type":75},"2032-08-31",{"name":43,"class":6},1]